ESR1 and breast cancer: In our study, we did not observe an apparent increased susceptibility to palbociclib monotherapy in ER+ BC cell lines compared to the TNBC cell lines in the [3H]thymidine incorporation assay, but the IncuCyte data clearly demonstrated increased growth suppression of the ER+ BC cell lines compared to the TNBC cell lines by palbociclib.